Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novavax (NVAX – Research Report) and Ramsay ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

Novavax Inc. closed 70.41% below its 52-week high of $23.86, which the company reached on June 6th.

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax (NVAX) stock in focus as company beats Q4 revenue forecasts despite an 80% drop in product sales. Read more here.